Cosmetic Industry Class Actions: Navigating New Risks Under Modernization of Cosmetics Regulation Act
Unapproved Drug Claims, Product Performance, False and Misleading Advertising, Mislabeling

Course Details
- smart_display Format
On-Demand
- signal_cellular_alt Difficulty Level
Intermediate
- work Practice Area
Class Action and Other Litigation
- event Date
Thursday, December 12, 2024
- schedule Time
1:00 p.m. ET./10:00 a.m. PT
- timer Program Length
90 minutes
-
This 90-minute webinar is eligible in most states for 1.5 CLE credits.
This CLE course will examine consumer class actions targeting the cosmetics industry under the increased scrutiny by the FDA as it continues implementing the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The panel will consider the possible impact of Loper Bright and how new FDA requirements already have and are expected to fuel class litigation. The panel will discuss theories of liability and strategies for defending and settling claims. The panel will also discuss proactive steps clients should take to minimize their exposure to class claims in light of increased FDA scrutiny and regulation.
Faculty

Mr. Gottfried focuses his practice on health care, as well as administrative and regulatory matters. He represents clients such as executives at large physician practice groups and hospital chains, compounding pharmacies, managed care organizations, ambulatory surgical centers, and home health agencies. Mr. Gottfried has experience working with numerous federal and state governmental agencies, and handles matters concerning the federal and Florida Anti-Kickback Statutes, the federal Stark Law, the federal and Florida False Claims Act, the federal Food, Drug, and Cosmetics Act, Florida’s Patient Brokering Act, and various hospital and physician billing laws and regulations.

Ms. Kolton has wide-ranging legal, administrative and management experience in medical practice law; HIPAA, Stark, Medicare and CMS regulations; with the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC); and other civil and administrative law areas. She possesses executive corporate experience and broad clinical background in a variety of health care settings, including the ability to understand scientific and medical community cultures, business challenges and concerns.

Ms. Miller is the Co-Chair of the Products Liability & Mass Torts Practice and focuses her practice in toxic tort, product liability, and class action litigation in state and federal courts. She is a trial lawyer with experience, both as first and second chair trial counsel, defending manufacturers against claims of product defect for industrial, automotive, and medical products on a national basis. As national counsel, Ms. Miller oversees products liability, toxic tort, and commercial litigation nationwide and counsels clients on risk management strategies. She also has wide-ranging experience litigating complex and mass tort litigation, both in the products liability and toxic tort context. In addition to her litigation practice, Ms. Miller counsels manufacturers, distributors and retailers regarding product safety issues and regulatory compliance. Her practice includes counseling clients on compliance with federal and state regulations, including regulations enforced by the Consumer Product Safety Commission and the National Highway Traffic Safety Administration, and providing guidance with recalls and recall procedures.

Ms. Pigott provides critical product liability advice and litigation defense to emerging and established businesses. As a shareholder in the Pharmaceutical, Medical Device & Health Care Litigation Practice, she manages products liability litigation matters with an emphasis on the defense of complex medical device and pharmaceutical products. Ms. Pigott handles high-stakes, single-plaintiff cases (including through trial) and complex litigation, including MDLs, coordinated state actions and class actions working as both national and regional counsel. She also works with companies to reduce and eliminate litigation risk through essential assessment and review of potential product liability exposure, including helping to organize and establish more effective claims handling in pre-litigation as well as in identifying and reducing risk producing activities and providing information to allow companies to understand triggers for potential exposure and manage such risks. In addition, Ms. Pigott has worked on a wide variety of other product liability matters, including welding products and consumables, automobiles, buses and private shuttles, airplanes, helicopters, rocket propelled parachute systems, soft drinks, and video games.
Description
Enacted in 2022, MoCRA completely overhauled the way the FDA regulates cosmetics, adding many new requirements, including requiring adverse event reporting and record keeping, labeling requirements, safety substantiation, and records access. These new mandates mean that companies must change how they manage the entire manufacturing, marketing, and sale process. Attempts to comply with and implement MoCRA create opportunities for missteps and offer fertile ground for class action litigation.
Private litigants are increasingly using state laws to enforce alleged violations of the federal Food, Drug, and Cosmetics Act. As more states outlaw specific ingredients, this activity is expected to increase. A number of class lawsuits have sought damages for implied drug claims and misbranded drugs (unapproved drug) because products allegedly did not conform to an FDA monograph.
Whether pursuing or defending class actions against cosmetics manufacturers, counsel must understand common and emerging liability theories and be able to navigate issues of predominance, standing, causation, and more. Further, defense counsel will want to help their industry clients take proactive steps to minimize the likelihood of class claims.
Listen as our authoritative panel of class action attorneys discusses how MoCRA is impacting class actions against cosmetic companies and best practices for minimizing liability exposure.
Outline
- History of cosmetics regulation in the U.S.
- New requirements and FDA enforcement powers
- Regulation of good manufacturing practices
- Claims
- Defenses
- Strategies for plaintitff and defense
Benefits
The panel will review these and other important issues:
- How does adverse incident reporting (or failure to report) create risk of class litigation?
- What is the difference between asserting that conduct violates the FDCA and attempting to enforce the FDCA?
- What defenses may be available under MoCRA?
Unlimited access to premium CLE courses:
- Annual access
- Available live and on-demand
- Best for attorneys and legal professionals
Unlimited access to premium CPE courses.:
- Annual access
- Available live and on-demand
- Best for CPAs and tax professionals
Unlimited access to premium CLE, CPE, Professional Skills and Practice-Ready courses.:
- Annual access
- Available live and on-demand
- Best for legal, accounting, and tax professionals
Related Courses

Authenticating Disputed E-Signatures at Trial: ESIGN and UETA, Experts, Burdens of Proof, Audit Trails
Friday, February 28, 2025
1:00 p.m. ET./10:00 a.m. PT

Concurrently and Ethically Representing Companies, Owners, and Employees in the Same Matter
Monday, May 19, 2025
1:00 p.m. ET./10:00 a.m. PT
Recommended Resources
Explore the Advantages of Consistent Legal Language
- Learning & Development
- Business & Professional Skills
- Talent Development